Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Amyloid-Beta Related Angiitis of the Central Nervous System: Case Report and Topic Review
Front Neurol 5:1-4, Nouh, A.,et al, 2014
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
Cerebral Amyloid Angiopathy
NEJM 394:1836-1845, Greenberg,S.M., 2026
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
A 67 YEar-Old Woman with Progressive Headache, Visual Hallucinations, and Seizures
Neurol 104:e213496, Gheihman,G.,et al, 2025
Diagnosing Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 103:e209548, Charidimou,A., 2024
Clinical,Neuroimaging,and Genetic Markers in Cerebral Amyloid Angiopatny-Related Inflammation:A Systematic Review and Meta-Analusis
Stroke 54:178-188, Theodorou,A.,et al, 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Clinicopathologic Conference, Cerebral Amyloid Angiopatny-Related Inflammation
NEJM 385:358-368, Case 22-2021, 2021
Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation
JAMA Neurol 73:197-202, Auriel, E.,et al, 2016
Pseudotumoral Presentation of Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 86:912-919, Ronsin, S.,et al, 2016
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Inflammatory Cerebral Amyloid Angiopathy, Amyloid-B-Related Angiitis, and Primary Angiitis of the Central Nervous System
Stroke 46:e210-e213, Moussaddy, A.,et al, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Amyloid Beta-Related Angiitis - A Case Report and Comprehensive Review of Literature of 94 Cases
Semin Arthritis Rheum 44:86-92, Danve, A.,et al, 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Cerebral Amyloid Angiopathy Related Inflammation: Three Case Reports and a Review
JNNP 82:20-26, Chung,K.K.,et al, 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Clinicopath Conf, Inflamatory Cerebral Amyloid Angiopathy,
NEJM 363:373-381, Case 22-2010, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Course of Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 68:1411-1416, Kinnecom,C.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Intracerebral Hemorrhage
The Neurologist 11:311-324, Badjatia,N. &Rosand,J., 2005
Clinical Manifestations of Cerebral Amyloid Angiopathy-Related Inflammation
Ann Neurol 55:250-256, Eng,J.A.,et al, 2004
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Immunization for Alzheimer's Disease: A Shot in the Arm or a Whiff?
Ann Neurol 48:553-555, Levey,A.I., 2000
Migraine in Pregnancy
Neurol 53:S26-S28, Aube,M., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Synergistic Immunomod Effects of Interferon-Beta1b & Phosphodiesterase Inhib Pentoxifylline in Pts with Relapsing-Remit MS
Ann Neurol 44:27-34, 71998., Weber,F.,et al, 1998
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
Treating Migraine, Try Stress Reduction and Simple Analgesia First
BMJ 299:141-142, Clough,C., 1989
10 Things You Should Know About Cerebral Amyloid Angiopathy
Stroke 57:e69-e742026, Charidimou,A.,
Status Epilepticus After Carotid Endarterectomy:An Illustrative Case of Cerebral Hyperfusion Syndrome
Stroke 57:e188-191, Reuter,P.,et al, 2026
A 28-Year-Old Man with Seizures and Thalamic Lesions
Neurol 106:e218065, Santos-Rojo,A.B.,et al, 2026